Robert Lakin

Robert Lakin

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

ASXC Stock: Why Popular Play Asensus Surgical Is Climbing Today

ASXC stock got an analyst 'buy' rating just days after reporting positive Q1 results. Asensus Surgical remains a worthy investment.

Ripple (XRP) Crypto News: 3 Big Reasons Bulls Are Backing Ripple Today

The Ripple crypto XRP is gaining ground today as the underlying company nabs new partnerships and high praise from CNBC.

RIDE Stock: Why Lordstown Motors Is Crashing and Burning Today

RIDE stock is slamming the breaks on even the most bullish investors as the company shares it needs more cash to make trucks.

STEM Stock: 2 Reasons the Energy Storage Play Is Charging Up Today

Stem has clear first-mover advantage with its AI-driven clean energy storage service offering. That story seems to be catching fire as investors stoke the share price for a fourth day.

CTRM Stock: What Is Going on With Popular Castor Maritime Today?

Castor Maritime moves to stay above the $1 per share Nasdaq minimum, with a 1-for-10 reverse stock split, effective on May 28. InvestorPlace contributors have been advising on the meme stock.

SPCE Stock: Virgin Galactic Soars as Investors Bet Big on Commercial Launch

Virgin Galactic is a step closer to full commercial operations after the successful third test flight of its VSS Unity spacecraft from Spaceport, New Mexico. SPCE stock gained last week in anticipation of the launch.

SPCE Stock: Why Virgin Galactic Is Taking Off This Morning

SPCE stock is rocketing higher after confirming that its next two test flights are on track. Here's what you should know now.

OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today

Swiss biopharma ObsEva is on course to introduce an oral treatment for uterine fibroids, which affect 80% of women by menopause.

MSTR Stock: Why MicroStrategy Is Tumbling Again Today

MSTR stock is suffering on Wednesday after the company added another $10 million in Bitcoin to its balance sheet.

Crypto Carnage: What to Know About BTC, ETH, ADA, XRP, DOGE Today

Regulators in Beijing and Washington have their sights on digital currencies. BTC-USD dropped below $40,000 to lead the crypto carnage.